Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy

Clinical Lung Cancer

Volumn 16, Issue 3, 2015, Pages 228-236

  Cha, Yoon Ki ^a   Lee, Ho Yun ^a   Ahn, Myung Ju ^a   Choi, Yoon La ^a   Lee, Ji Hyun ^a   Park, Keunchil ^a   Lee, Kyung Soo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Predictor; Tumor burden; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IOMEPROL; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADRENAL METASTASIS; ADULT; ADVANCED CANCER; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL INDICATOR; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; ADENOCARCINOMA; AGED; DISEASE COURSE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84928703650     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.11.002     Document Type: Article

References (41)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
3. T. Takano, T. Fukui, and Y. Ohe EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan J Clin Oncol 26 2008 5589 5595
4. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
5. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
6. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
7. A. Inoue, K. Kobayashi, and M. Maemondo Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Ann Oncol 24 2013 54 59
8. J.Y. Han, K. Park, and S.W. Kim First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30 2012 1122 1128
9. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
10. H.A. Yu, M.E. Arcila, and N. Rekhtman Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 2013 2240 2247
11. S. Maheswaran, L.V. Sequist, and S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
12. M. Takeda, I. Okamoto, and K. Nakagawa Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib J Thorac Oncol 9 2014 200 204
13. J.H. Park, T.M. Kim, and B. Keam Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib Clin Lung Cancer 14 2013 383 389
14. J.Y. Lee, S.H. Lim, and M. Kim Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Cancer Chemother Pharmacol 73 2014 1063 1070
15. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
16. S. Yuan, S.L. Yu, and H.Y. Chen Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations J Clin Oncol 29 2011 3435 3442
17. Q. Zhou, X.C. Zhang, and Z.H. Chen Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer J Clin Oncol 29 2011 3316 3321
18. R. Rosell, M.A. Molina, and C. Costa Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations Clin Cancer Res 17 2011 1160 1168
19. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
20. J.L. Kuiper, and E.F. Smit Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors Oncology 87 2014 83 94
21. W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
22. C. Ma, S. Wei, and Y. Song T790M and acquired resistance of EGFR TKI: a literature review of clinical reports J Thorac Dis 3 2011 10 18
23. X. Zhang, and A. Chang Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer Int J Med Sci 5 2008 209 217
24. J.M. Sun, M.J. Ahn, and Y.L. Choi Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors Lung Cancer 82 2013 294 298
25. D.M. Jackman, B.Y. Yeap, and L.V. Sequist Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib Clin Cancer Res 12 2006 3908 3914
26. G.J. Riely, W. Pao, and D. Pham Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 12 2006 839 844
27. K. Goto, M. Nishio, and N. Yamamoto A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) Lung Cancer 82 2013 109 114
28. C.H. Yang, C.J. Yu, and J.Y. Shih Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy J Clin Oncol 26 2008 2745 2753
29. H. Asahina, K. Yamazaki, and I. Kinoshita A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br J Cancer 95 2006 998 1004
30. A. Inoue, T. Suzuki, and T. Fukuhara Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 2006 3340 3346
31. T. Kosaka, Y. Yatabe, and R. Onozato Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol 4 2009 22 29
32. L.V. Sequist, R.G. Martins, and D. Spigel First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J Clin Oncol 26 2008 2442 2449
33. Y. Zhang, J. Sheng, and S. Kang Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis PLoS One 9 2014 e107161
34. R.A. Joss, K. Burki, and P. Dalquen Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer: association of antitumor activity with initial tumor burden and treatment center Cancer 65 1990 2426 2434
35. B.M. Alexander, M. Othus, H.B. Caglar, and A.M. Allen Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 79 2011 1381 1387
36. S. Liao, B.C. Penney, and K. Wroblewski Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer Eur J Nucl Med Mol Imaging 39 2012 27 38
37. M.J. Chen, W. Zhong, and L. Zhang Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib Chin Med J (Engl) 126 2013 2235 2241
38. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
39. F.C. Detterbeck, D.J. Boffa, and L.T. Tanoue The new lung cancer staging system Chest 136 2009 260 271
40. J. Foo, and F. Michor Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies PLoS Comput Biol 5 2009 e1000557
41. J. Chmielecki, J. Foo, and G.R. Oxnard Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling Sci Transl Med 3 2011 90ra59